Your session is about to expire
← Back to Search
Cannabinoid
THC + Ketamine for Cannabis and Ketamine
Phase 1
Waitlist Available
Led By Rajiv Radhakrishnan, M.D.
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up -60, +70, +120, +240 from baseline (0) (units in minutes).
Awards & highlights
Study Summary
This trial will assess the safety of combining the drugs ketamine and THC, as well as the effects of the combination on cognition and behavior.
Eligible Conditions
- Cannabis
- Ketamine
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ -60, +70, +120, +240 from baseline (0) (units in minutes).
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~-60, +70, +120, +240 from baseline (0) (units in minutes).
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
EEG Measures 1
EEG Measures 2
EEG Measures 3
+6 moreSecondary outcome measures
Cannabis Subjective Effects
Perceptual Alterations
Positive and Negative Symptoms Scale (PANSS)
Trial Design
4Treatment groups
Experimental Treatment
Group I: Placebo Delta-9-THC and Placebo KetamineExperimental Treatment2 Interventions
IV Placebo Delta-9-THC and Placebo Ketamine
Group II: Placebo Delta-9-THC and Active KetamineExperimental Treatment2 Interventions
IV Placebo Delta-9-THC and Active Ketamine
Group III: Active Delta-9-THC and Placebo KetamineExperimental Treatment2 Interventions
Active IV Delta-9-THC and Placebo Ketamine
Group IV: Active Delta-9-THC and Active KetamineExperimental Treatment2 Interventions
Active IV Delta-9-THC and Active Ketamine
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo Ketamine
2019
Completed Phase 1
~30
Active Delta-9-THC
2015
Completed Phase 1
~60
Placebo Delta-9-THC
2019
Completed Phase 1
~30
Active Ketamine
2019
Completed Phase 1
~30
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Brain & Behavior Research FoundationOTHER
61 Previous Clinical Trials
2,792 Total Patients Enrolled
Yale UniversityLead Sponsor
1,848 Previous Clinical Trials
2,737,796 Total Patients Enrolled
14 Trials studying Cannabis
802 Patients Enrolled for Cannabis
Rajiv Radhakrishnan, M.D.Principal InvestigatorYale University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Active Delta-9-THC and Active Ketamine
- Group 2: Active Delta-9-THC and Placebo Ketamine
- Group 3: Placebo Delta-9-THC and Active Ketamine
- Group 4: Placebo Delta-9-THC and Placebo Ketamine
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger